咖啡/咖啡因对多发性硬化症患者的影响; 一个系统性审查
Shabnam Salekzamani1, Saman Baharomid2, Sina Pakkhesal2
1Department of Nutrition, Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran.
Journal of evidence-based integrative medicine
|October 26, 2024
概括
咖啡消费可能会改善多发性硬化症 (MS) 患者的认知功能,但似乎不会影响疾病残疾. 由于证据有限,需要进一步研究.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
- 公共卫生 公共卫生
背景情况:
- 多发性硬化症 (MS) 是一种中枢神经系统脱髓化的疾病.
- 咖啡因是一种广泛消费的精神活性物质,可能会影响MS的临床过程和残疾.
- 了解咖啡/咖啡因对MS患者的影响对于患者护理至关重要.
研究的目的:
- 系统地审查有关咖啡/咖啡因消费对多发性硬化症患者影响的现有证据.
- 评估咖啡因摄入量与临床结果之间的关系,包括MS的认知功能和残疾水平.
- 综合发现并为临床实践提供谨慎的建议.
主要方法:
- 在PubMed,Scopus,Web of Science和Embase进行了系统的文献搜索.
- 遵守乔安娜·布里格斯研究所 (JBI) 证据综合手册和PRISMA 2020声明.
- 使用JBI工具对包含的研究进行批判性评估,以评估偏见风险.
主要成果:
- 在297个选记录中,有8项研究符合纳入标准.
- 研究设计包括回顾性队列,RCT,交叉,试点和横截面研究.
- 在咖啡/咖啡因摄入量和MS残疾水平之间没有发现显著的关联; 报告了认知改善.
结论:
- 有证据表明,咖啡/咖啡因消费与多发性硬化症患者的增强认知结果之间存在联系.
- 在咖啡/咖啡因摄入量和与疾病相关的残疾之间没有发现实质性关系.
- 由于研究有限和方法不同,研究结果应谨慎解释.
相关概念视频
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...